48,847
edits
Difference between revisions of "Neuropathology tumours"
Jump to navigation
Jump to search
m
Neuropathology tumours (view source)
Revision as of 06:00, 24 November 2010
, 06:00, 24 November 2010→Glioblastoma IHC: do refs
m (→Gross: fix ref) |
m (→Glioblastoma IHC: do refs) |
||
| Line 99: | Line 99: | ||
*p53 - often +ve. | *p53 - often +ve. | ||
*IDH1 (isocitrate dehydrogenase 1). | *IDH1 (isocitrate dehydrogenase 1). | ||
**+ve in tumours that arose from low-grade gliomas.<ref name=pmid19228619> | **+ve in tumours that arose from low-grade gliomas.<ref name=pmid19228619>{{cite journal |author=Yan H, Parsons DW, Jin G, ''et al.'' |title=IDH1 and IDH2 mutations in gliomas |journal=N. Engl. J. Med. |volume=360 |issue=8 |pages=765–73 |year=2009 |month=February |pmid=19228619 |pmc=2820383 |doi=10.1056/NEJMoa0808710 |url=}}</ref> | ||
***Image: [http://en.wikipedia.org/wiki/File:IDH1_GBM_20x.jpg IDH1 +ve in glioblastoma (WP)]. | ***Image: [http://en.wikipedia.org/wiki/File:IDH1_GBM_20x.jpg IDH1 +ve in glioblastoma (WP)]. | ||
Notes: | Notes: | ||
*IDH1 and IDH2 mutations - better survival.<ref name=pmid20975057> | *IDH1 and IDH2 mutations - better survival.<ref name=pmid20975057>{{cite journal |author=Houillier C, Wang X, Kaloshi G, ''et al.'' |title=IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas |journal=Neurology |volume=75 |issue=17 |pages=1560–6 |year=2010 |month=October |pmid=20975057 |doi=10.1212/WNL.0b013e3181f96282 |url=}}</ref> | ||
==Pilocytic astrocytoma== | ==Pilocytic astrocytoma== | ||